Star Combo Pharma Limited has updated its Corporate Governance Statement, outlining its adherence to the recommendations set by the ASX Corporate Governance Council for the financial year ended June 2026. The company has disclosed its respective roles and responsibilities of the board and management, as well as its diversity policy and the processes for evaluating board performance.
Material actions and disclosures
The company has disclosed its commitment to having a diversity policy which includes requirements for the board to set measurable objectives for achieving gender diversity and to assess annually both the objectives and the entity’s progress in achieving them. Additionally, Star Combo Pharma Limited has detailed its whistleblower policy and its adherence to ethical and responsible practices.
The company also disclosed its risk management framework, including the processes for overseeing risk and the review of the entity’s risk management framework annually to ensure it remains sound.
Star Combo Pharma Limited has also provided information on its remuneration practices, including the setting of remuneration for directors and senior executives, and the processes in place to ensure that such remuneration is appropriate and not excessive.
Further details on the company’s corporate governance practices can be found at http://investors.starcombo.com.au/Investors/.